Webinar
How integrated real-world data is reshaping GLP-1 commercial strategy
For GLP-1 therapies, the gap between clinically eligible and treated patients represents one of the largest commercial opportunities in obesity. Roughly two-thirds of clinically eligible overweight/obese patients are invisible to claims-only approaches.
This webinar explores how integrated longitudinal claims, clinically rich EMR data (including BMI and unstructured clinical notes), and near real-time prescription activity provide earlier visibility into obesity treatment opportunity, prescribing shifts, untreated patient populations, and access barriers.
Near real-time prescription data reveals prescribing trends in approximately 2 days versus the several weeks-to-months lag associated with traditional claims and EMR datasets.
In this webinar, our experts will discuss how linked patient-level visibility across clinical, prescribing, and longitudinal healthcare activity can support more informed commercial, market access, and evidence-generation strategies.
You will learn:
- How to identify clinically eligible obesity and GLP-1 patient populations beyond traditional claims-based approaches using integrated EMR, claims, clinical notes, and real-time prescription data
- How to uncover prescribing momentum, untreated patient pools, access barriers, and patient drop-off across the GLP-1 treatment journey
- How to apply near real-time insights to optimize HCP targeting, commercial deployment strategy, payer engagement, and HEOR evidence generation
- How integrated longitudinal data can provide a more complete view of patient, provider, payer, and health-system dynamics shaping GLP-1 adoption
Get access to GLP-1 market insights
Our experts
Daniel Chancellor
VP, Thought Leadership, Norstella
Dan has over 15 years of experience across biopharma, working in roles spanning drug discovery, market analysis, competitive intelligence, and strategic consulting. He leads the thought leadership program at Norstella, where he and his team produce research and insights that help clients navigate evolving industry challenges.
Allison Perry, PhD
VP, RWD Commercial Strategy & Innovation, Head of RWD Strategy Team, Norstella
Allison partners with life sciences companies to unlock the value of Norstella’s real-world data across commercial, medical, HEOR, and regulatory use cases. A Ph.D.-trained epidemiologist, she has extensive experience leading real-world data strategy across CROs, data vendors, and pharma.
Ilan Behm, MPH
Head of RWD Commercial Strategy & Innovation, Norstella
Ilan brings 20 years of healthcare analytics experience, driving client success at Norstella through real-world data expertise. He has a background in payer strategy using claims data and now leads teams leveraging claims, lab, and EMR data to deliver meaningful client impact.
